Status:
COMPLETED
Drug Interaction Study - Effect of AZD5672 on the Pharmacokinetics of Digoxin
Lead Sponsor:
AstraZeneca
Conditions:
Healthy Volunteers
Pharmacokinetics
Eligibility:
All Genders
18-50 years
Phase:
PHASE1
Brief Summary
The purpose of the study is to examine the effect of AZD5672 (dosed to steady state) on the pharmacokinetics of digoxin (single dose administration).
Eligibility Criteria
Inclusion
- Provision of signed written informed consent.
- Females should not be of childbearing potential
- Clinically normal physical and laboratory findings as judged by the investigator, including negative drug test and negative tests of Hepatitis B surface antigen, antibodies to Hepatitis C virus and antibodies to HIV.
Exclusion
- Any clinically significant disease or disorder which, in the opinion of the investigator, may either put the subject at risk because of participation in the study, or may influence the results of the study, or the subject's ability to participate
- Known allergy to digoxin or previous complications to digoxin therapy.
- Participation in any clinical study involving an investigational product in the 3 months prior to enrolment.
Key Trial Info
Start Date :
July 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 1 2008
Estimated Enrollment :
24 Patients enrolled
Trial Details
Trial ID
NCT00723424
Start Date
July 1 2008
End Date
December 1 2008
Last Update
December 2 2010
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Research Site
Berlin, Germany